Anesthesiology and Pain Medicine

Published by: Kowsar

Unrestricted and Restricted Access to Sugammadex and Side Effect Profile in a Teaching Hospital Centre for Year 2014- Database Audit Study

Vasanth Rao Kadam 1 , * and Stuart Howell 2
Authors Information
1 Department of Anaesthesia, the Queen Elizabeth Hospital and Senior Clinical Lecturer, School of Medicine, University of Adelaide, Adelaide, South Australia
2 Senior Statistician, Data, Design and Statistics Service, Adelaide Health Technology Assessment (AHTA), School of Public Health, University of Adelaide, Adelaide, South Australia
Article information
  • Anesthesiology and Pain Medicine: February 2018, 8 (1); e63066
  • Published Online: February 17, 2018
  • Article Type: Research Article
  • Received: October 24, 2017
  • Revised: December 12, 2017
  • Accepted: January 28, 2018
  • DOI: 10.5812/aapm.63066

To Cite: Rao Kadam V, Howell S. Unrestricted and Restricted Access to Sugammadex and Side Effect Profile in a Teaching Hospital Centre for Year 2014- Database Audit Study, Anesth Pain Med. 2018 ; 8(1):e63066. doi: 10.5812/aapm.63066.

Abstract
Copyright © 2018, Anesthesiology and Pain Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
References
  • 1. Godai K, Hasegawa-Moriyama M, Kuniyoshi T, Kakoi T, Ikoma K, Isowaki S, et al. Three cases of suspected sugammadex-induced hypersensitivity reactions. Br J Anaesth. 2012;109(2):216-8. doi: 10.1093/bja/aes137. [PubMed: 22617091].
  • 2. Takazawa T, Tomita Y, Yoshida N, Tomioka A, Horiuchi T, Nagata C, et al. Three suspected cases of sugammadex-induced anaphylactic shock. BMC Anesthesiol. 2014;14:92. doi: 10.1186/1471-2253-14-92. [PubMed: 25349529].
  • 3. Jeyadoss JKP, Nanjappa N, Van Wijk R. Sugammadex hypersensitivity-a case of anaphylaxis. AnaesIntens Care. 2014;42(1):89-92.
  • 4. Takahiro THN, Mae T, Doi K, Ozaki M. Be careful about anaphylactic shock by antagonism of the neuromuscular blockade~ cases of anaphylactic shock induced by sugammadex. Critical Care Med. 2012;40(1):1145.
  • 5. Tokuwaka J, Takahashi S, Tanaka M. Anaphylaxis after sugammadex administration. Can J Anaesth. 2013;60(7):733-4. doi: 10.1007/s12630-013-9931-9. [PubMed: 23591858].
  • 6. Motoyama Y, Izuta S, Maekawa N, Chuma R. [Case of anaphylactic reaction caused by sugammadex]. Masui. 2012;61(7):746-8. [PubMed: 22860305].
  • 7. Takeda J, Iwasaki H, Otagiri T, Katoh T, Shingu K, Obara H, et al. [Efficacy and safety of sugammadex (Org 25969) in reversing deep neuromuscular block induced by rocuronium or vecuronium in Japanese patients]. Masui. 2014;63(10):1083-8. [PubMed: 25693333].
  • 8. Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia. 2014;69(11):1251-7. doi: 10.1111/anae.12736. [PubMed: 24848211].
  • 9. Savic L, Savic S, Hopkins PM. Anaphylaxis to sugammadex. Anaesth Intensive Care. 2014;42(1):7-9. [PubMed: 24494255].
  • 10. Baldo BA, McDonnell NJ. Sugammadex and anaphylaxis in the operating theater. Rev Esp Anestesiol Reanim. 2014;61(5):239-45. doi: 10.1016/j.redar.2014.02.005. [PubMed: 24666509].
  • 11. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104(4):667-74. [PubMed: 16571960].
  • 12. Watts RW, London JA, van Wijk RM, Lui YL. The influence of unrestricted use of sugammadex on clinical anaesthetic practice in a tertiary teaching hospital. Anaesth Intensive Care. 2012;40(2):333-9. [PubMed: 22417030].
  • 13. Ledowski T, Falke L, Johnston F, Gillies E, Greenaway M, De Mel A, et al. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. Eur J Anaesthesiol. 2014;31(8):423-9. doi: 10.1097/EJA.0000000000000010. [PubMed: 24296853].
  • 14. Abad-Gurumeta A, Ripolles-Melchor J, Casans-Frances R, Espinosa A, Martinez-Hurtado E, Fernandez-Perez C, et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia. 2015;70(12):1441-52. doi: 10.1111/anae.13277. [PubMed: 26558858].
  • 15. Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev. 2009;(4). CD007362. doi: 10.1002/14651858.CD007362.pub2. [PubMed: 19821409].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments